about
Optimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaIntegrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid TumorsTargetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or LeukemiaSelective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsSpatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.Vincristine: Can its therapeutic index be enhanced?Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Novel therapies for children with acute myeloid leukaemia.Intertumoral Heterogeneity within Medulloblastoma Subgroups.The MLL recombinome of acute leukemias in 2017.A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion.Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?Erratum to: Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours.Targeted Next-Generation Sequencing for Detecting MLL Gene Fusions in Leukemia.EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.ALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine gliomaLocalised peripheral primitive neuroectodermal tumour (PNET) of the conjunctivaA stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assayVincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approachOutcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 childrenInfant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomesPTEN deletion drives acute myeloid leukemia resistance to MEK inhibitorsAssessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study
P50
Q27674324-47BFC23F-F063-4C25-A09D-470E68286226Q33882326-1CA2B9FA-C2E2-4DAF-B315-D5BEB34BEF3BQ34314927-8C9428E7-7FED-4408-BE40-B66F545FB56EQ34515911-49198F0A-E5B3-4CC7-91FF-42D3735DADE7Q35049985-DFEB1DDB-D33D-4A4A-87A7-559FCA9498A0Q35666005-2FC13006-FAB6-41DC-ACBC-D3C11B15CF12Q35666005-7C059E24-33EF-4846-AFD3-6CE354EA826CQ36469916-4FDA0296-D2E7-4197-A7DB-194D37C60886Q36774588-17067FE8-37F2-43B3-9A05-ACF8A4FEEE01Q37004219-45C471A5-B0A3-4E4C-B25A-3EEC140DE358Q37305758-341E61D1-8067-496D-AA78-B76F8305FC35Q37545848-0938E441-91FC-4F17-A66B-48C8F986555FQ37690579-2E7B8A34-ED00-4A90-AA2A-BE5A3F956184Q38096798-9C17B5C8-82C2-4DC0-8448-55CF87C5E789Q38671456-A254E8A9-414B-49FD-9394-5A2AAED40FA9Q38681972-1062361F-C72D-48D2-AF16-53A4F1173E8CQ38788657-FB400350-98DA-4665-8C33-36D138A21D2DQ39526264-2B59D202-A416-431E-93F6-396F88A612C9Q40859498-F53F0F2B-199C-4306-ADD1-F5A7464694F9Q41099096-DBDCC91A-911C-4A72-BE19-83227C722296Q41467756-3A0B774A-02ED-415C-B0B8-3115EC33F797Q42375231-0D43F855-A0EB-4A4C-8AD1-FE121FD601CAQ43092984-3516035F-A8E1-4BEF-8C34-12324545EC1EQ47142310-9A703524-22AB-4AE4-9B5D-3C6D85DF9D66Q47853157-C02B6F26-6079-4645-BCB4-A9A38D69B6E4Q47864993-A505F472-8352-4D5D-86C2-3F78B8A99A21Q48231823-3643119E-893D-4430-A116-5D621E110E1AQ48303270-32EEFD24-0513-4655-9B1A-602E6FCC57CCQ49802373-16E75514-C232-4161-B661-8543A8784F98Q50042497-9A8F9D3A-EFA1-4332-98C2-EB5EB3A83BCBQ51283425-0A39B339-EED6-401F-9F36-E6A58FC275A3Q52310957-DB275D9D-9DBA-482E-9221-96A6F0AE2391Q55456542-D2D0B082-5640-4780-B3D9-C0E662A6E775Q64059831-E7815C09-A8FF-4E46-AB22-66CB6CE7B893Q83984423-DC0C596D-D5F9-43BC-AF7C-CF9CA4F43FE9Q84170546-9686A691-864B-4B9A-8E8B-80D87270AD7CQ84317550-A9C90231-4B59-42A0-8A99-A52DE133D784Q89505912-369F66F3-E307-4844-AED4-92A84EC10343Q90832636-14ACC0F4-5D6A-4D31-877D-28A6B406709EQ90912327-CB5A5633-7270-4ABD-AC49-8B448F59BF19
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew S Moore
@ast
Andrew S Moore
@en
Andrew S Moore
@es
Andrew S Moore
@nl
Andrew S Moore
@sl
type
label
Andrew S Moore
@ast
Andrew S Moore
@en
Andrew S Moore
@es
Andrew S Moore
@nl
Andrew S Moore
@sl
prefLabel
Andrew S Moore
@ast
Andrew S Moore
@en
Andrew S Moore
@es
Andrew S Moore
@nl
Andrew S Moore
@sl
P106
P21
P31
P496
0000-0001-8062-1779